OBJ : 28 October 2016 / AGM Presentation 2016

This Presentation has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ or the Company). This Presentation contains summary information about OBJ and its activities current as at the date of this Presentation. The information in this Presentation is of general background and does not purport to be complete or to comprise all

the information that a shareholder or potential investor in OBJ may require in order to determine whether to deal in OBJ shares. It should be read in conjunction with OBJ's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au. This document is not a prospectus or a product disclosure statement

under the Corporations Act (Cth) 2001 (Corporations Act) and has

not been lodged with the Australian Securities and Investments Commission (ASIC).

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain "forward-looking statements". The words "expect", "should", "could", "may", "will, "predict", "plan", "scenario", "forecasts", "anticipates", "outlook" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Such forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with the Company and the industry (including those set out below) which may affect the accuracy of the forward-looking statements. The Company does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

This document may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. Securities in the Company have not been, and will not be, registered under the U.S. Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States unless the securities are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration. To the maximum extent permitted by law, OBJ and its respective advisers and affiliates, directors, officers and employees make no representation or warranty, express or implied, as to the accuracy, reliability or completeness of information in the Presentation.

OVERVIEW

• Life sciences company focused on product performance enhancement through physical rather

  than chemical means.

• Executed new Product Development Agreement with Procter & Gamble (P&G) that extends to 2021.

• The Eye Wand for Olay & SKII now launched in China with other countries to follow.

• Licensing Term Sheet for second Licensed product (Wave II) committed and launch planned 2017

• Wave III, Wave IV Wave V and Wave VI in late stage development.

• Master License Agreement (MLA) executed, covering all products to be licensed to P&G.

• Bodyguard - major clinical trial & consumer research study completed with outstanding results

  - manufacturing research & discussions with four potential distributors maturing.

• Studies for surface hygiene reconfirmed 300% increase in the kill rate of Golden Staph.

  Laboratory testing by two major potential partners underway

• Revenues from Wave 1 (Olay & SK-II) commencing December 2016 & Wave II June 2017.

THE SCIENCE OF DIAMAGNETIC REPULSION

Driving performance through physical rather than chemical science.